Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

BUY
$6.7 - $24.21 $1.67 Million - $6.02 Million
248,847 Added 216.56%
363,758 $8.77 Million
Q4 2022

Feb 14, 2023

SELL
$4.52 - $10.57 $308,395 - $721,180
-68,229 Reduced 37.26%
114,911 $1.21 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.62 $336,284 - $550,996
98,042 Added 115.21%
183,140 $824,000
Q2 2022

Aug 15, 2022

BUY
$3.65 - $7.3 $114,610 - $229,220
31,400 Added 58.48%
85,098 $340,000
Q1 2022

May 16, 2022

SELL
$3.4 - $7.88 $470,957 - $1.09 Million
-138,517 Reduced 72.06%
53,698 $393,000
Q4 2021

Feb 14, 2022

BUY
$5.59 - $7.39 $568,721 - $751,851
101,739 Added 112.45%
192,215 $1.08 Million
Q3 2021

Nov 15, 2021

SELL
$5.66 - $8.33 $1.26 Million - $1.86 Million
-223,098 Reduced 71.15%
90,476 $579,000
Q2 2021

Aug 11, 2021

BUY
$6.71 - $11.04 $439,236 - $722,678
65,460 Added 26.38%
313,574 $2.64 Million
Q1 2021

May 17, 2021

BUY
$10.12 - $19.45 $515,988 - $991,697
50,987 Added 25.87%
248,114 $2.6 Million
Q4 2020

Feb 16, 2021

BUY
$11.79 - $18.94 $498,492 - $800,802
42,281 Added 27.31%
197,127 $3.34 Million
Q3 2020

Nov 16, 2020

BUY
$10.34 - $15.2 $379,974 - $558,569
36,748 Added 31.12%
154,846 $1.99 Million
Q2 2020

Aug 14, 2020

SELL
$7.81 - $17.0 $1.88 Million - $4.09 Million
-240,503 Reduced 67.07%
118,098 $1.67 Million
Q1 2020

May 15, 2020

BUY
$5.42 - $17.75 $857,709 - $2.81 Million
158,249 Added 78.99%
358,601 $3.3 Million
Q4 2019

Feb 14, 2020

BUY
$5.84 - $14.9 $924,273 - $2.36 Million
158,266 Added 376.05%
200,352 $2.99 Million
Q3 2019

Nov 14, 2019

BUY
$6.83 - $13.0 $111,684 - $212,576
16,352 Added 63.54%
42,086 $287,000
Q2 2019

Aug 16, 2019

BUY
$2.3 - $13.79 $6,626 - $39,728
2,881 Added 12.61%
25,734 $311,000
Q2 2019

Aug 14, 2019

BUY
$2.3 - $13.79 $52,561 - $315,142
22,853 New
22,853 $277,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.